PCDH9-AS4: A Potential Drug Target and Biomarker (G100874087)

Target Name: PCDH9-AS4

NCBI ID: G100874087

PCDH9-AS4

Other Name(s): PCDH9 antisense RNA 4

PCDH9-AS4: A Potential Drug Target and Biomarker

Polygenic Programming Disruptive (PCDH) genes are a family of non-coding RNAs that play a crucial role in the development and progression of many diseases, including cancer. One of the most well-studied PCDH genes is PCDH9, which has been implicated in the development and progression of various types of cancer. In recent years, researchers have also been interested in investigating the potential drug targets and biomarkers associated with PCDH9. In this article, we will focus on PCDH9-AS4, a potential drug target and biomarker associated with PCDH9.

PCDH9-AS4: Structure and Function

PCDH9 is a 21 kDa RNA molecule that contains 11 exons and 10 introns. It is expressed in various tissues and cell types, including stem cells, lung cells, and cancer cells. PCDH9 has been shown to play a role in the development and progression of various types of cancer, including lung adenocarcinoma, a type of lung cancer that is the most common cause of cancer death in the United States.

PCDH9-AS4 is a splicing variant of PCDH9 that has been shown to have unique functions in various cell types. One of the most significant differences between PCDH9-AS4 and PCDH9 is the presence of an exonic addition at position -202. This exonic addition is located within the first exon of PCDH9 and results in a protein with a unique N-terminus.

Functional studies have shown that PCDH9-AS4 has a number of unique properties that make it an attractive drug target. For example, it has a more favorable expression pattern than PCDH9, with higher levels of expression in certain cell types and tissues. Additionally, PCDH9-AS4 has been shown to have unique functions in various cellular processes, including cell growth, apoptosis, and angiogenesis.

Despite its unique functions, PCDH9-AS4 is still a member of the PCDH9 gene family and is expressed in many of the same tissues and cell types as PCDH9. This makes it a potential biomarker for PCDH9-related diseases, as well as a potential drug target for PCDH9-AS4.

PCDH9-AS4 as a Drug Target

PCDH9-AS4 has been shown to have a number of unique functions that make it an attractive drug target. One of the most significant functions of PCDH9-AS4 is its role in cell growth and angiogenesis.

Studies have shown that PCDH9-AS4 plays a role in regulating cell growth and cell survival. For example, researchers have shown that PCDH9-AS4 can inhibit the growth of cancer cells in cell culture and in animal models of cancer. Additionally, PCDH9-AS4 has been shown to promote the growth of stem cells and induce them to differentiate into functional tissues, such as brain and heart cells.

PCDH9-AS4 has also been shown to play a role in the development of new blood vessels in the tumor. This is a critical step in the process of tumor growth and progression, and is a potential target for anti-cancer drugs.

Another function of PCDH9-AS4 is its role in apoptosis, which is the process by which cells die when they have reached a certain level of stress or damage. Studies have shown that PCDH9-AS4 can induce apoptosis in cancer cells, and that this function may be a potential target for anti-cancer drugs.

PCDH9-AS4 has also been shown to play

Protein Name: PCDH9 Antisense RNA 4

The "PCDH9-AS4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PCDH9-AS4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets